Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Melanoma
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant DiseasePHILADELPHIA, April 27, 2026...
Medical Care Technologies Inc. (OTC PINK:MDCE) Accelerates Growth Strategy with Strategic Capital Raise Following Launch of AI Consumer Platform
MESA, AZ / ACCESS Newswire / April 23, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a strategic...
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing...
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier...
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models...
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells...
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to...
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor...
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinomaPHILADELPHIA, April 17,...
Medical Care Technologies (OTC PINK:MDCE) Reaffirms Commitment to AI-Driven Medical Innovation Following Successful Consumer App Launch
Company leverages proven AI deployment capabilities to accelerate clinical-grade healthcare solutions. MESA, AZ / ACCESS Newswire / April 16, 2026...
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage...
World Tumor Registry Launches Breast Cancer Registry
PITTSBURGH, PA / ACCESS Newswire / April 14, 2026 / The World Tumor Registry ("WTR"), a global non-profit organization with...
Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd...
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced...
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and...